Faculty profile

Aru Narendran

ResearcherPediatricsUniversity of Calgary

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses may be missing. Find their university profile.

Aru Narendran

Researcher

Pediatrics

Health Sciences

University of Calgary

Calgary, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
21 publications in the last five years, latest in 2026.
Senior (last) author on 15 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.
Supervised 1 trainee who won CIHR awards, most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Adenine Base Editing Gene Editing Gene Therapy Clinical Trial Inborn Errors Of Immunity Rare Diseases Severe Combined Immune Deficiency

Latest papers

Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis.
Nature · 2026
Gene alterations in inborn errors of immunity and their presence in cancers: Implications for oncogenesis, progression, and outcomes.
Human immunology · 2026 · senior author
Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.
Targeted oncology · 2026

All 82 publications

Latest funding

Using genetically engineered type 2 innate lymphoid cells to enhance T cell-based immunotherapies for the treatment of breast cancer
CIHR · 2024 · Supervisor
$120,000
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
CIHR · 2022 · Principal investigator
$606,576
A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.
CIHR · 2022 · Principal investigator
$2,426,302

All 4 grants and awards

82 publications.

Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Mark MT, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D

Nature2026

DOI: 10.1038/s41586-026-10977-8 PMID: 42557336

Gene alterations in inborn errors of immunity and their presence in cancers: Implications for oncogenesis, progression, and outcomes.

Lokanc S, Sipila P, Cuvelier GDE, Murguía-Favela L, Wright NA, Grunebaum E, Bose P, Narendran A

Human immunology2026Senior author

DOI: 10.1016/j.humimm.2026.111671 PMID: 41616493

Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.

Rubio-San-Simón A, Marshall LV, Doz F, Mora J, Bielamowicz K, Corradini N, Langevin AM, Narendran A, Smith AA, Zwaan CM, Gho D, Cardenas A, Fowler S, Guizani C, Breton V, Wulff B, Bernardi R, Trippett T, Campbell-Hewson Q

Targeted oncology2026

DOI: 10.1007/s11523-025-01186-w PMID: 41379293

PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.

Sipila P, Zhao Y, Thakur S, Malhotra M, Zhang C, Willetts L, Murguia-Favela L, Narendran A

Human vaccines & immunotherapeutics2025Senior author

DOI: 10.1080/21645515.2025.2567703 PMID: 41055008

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

Sharma R, Zhang C, Shah R, Frigault MM, Johnson AJ, Mangum DS, Maese LD, Lacayo NJ, Narendran A

Blood neoplasia2025Senior author

DOI: 10.1016/j.bneo.2025.100148 PMID: 40979068

Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma.

Sipila P, Tran S, Zhang C, Douglass D, Langevin AM, Narendran A

Scientific reports2025Senior author

DOI: 10.1038/s41598-025-20994-8 PMID: 41131073

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

Boklan J, Langevin AM, Bielamowicz K, Neville K, Trippett T, Brown V, DuBois SG, Eshun F, Gelfond J, Zomet A, Narendran A, Lacayo NJ

Cancers2025

DOI: 10.3390/cancers17172924 PMID: 40941020

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma.

Tran S, Sipila P, Frigault MM, Stelte-Ludwig B, Johnson AJ, Birkett J, Izumi R, Hamdy A, Maity R, Bahlis NJ, Neri P, Narendran A

Blood neoplasia2025Senior author

DOI: 10.1016/j.bneo.2024.100050 PMID: 40546728

Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10.

Tran S, Sipila P, Thakur S, Zhang C, Narendran A

Cancers2024Senior author

DOI: 10.3390/cancers16081520 PMID: 38672602

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.

Sarkar S, Chanda A, Khanolkar RA, Lambie M, Ailles L, Bratman SV, Narendran A, Bose P

Biomedicines2024

DOI: 10.3390/biomedicines12030503 PMID: 38540116

Using genetically engineered type 2 innate lymphoid cells to enhance T cell-based immunotherapies for the treatment of breast cancer

SupervisorCIHR2024Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Kinzel, Megan E

Keywords: Breast Cancer; Flow Cytometry; Genetic Engineering; Immunotherapy; Innate Lymphoid Cells; Tumour Microenvironment

$120,000

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

Principal investigatorCIHR2022Operating Grant: Clinical Trials Projects - Indirect Costs

Principal investigators: Wright, Nicola A; Cuvelier, Geoff; Grunebaum, Eyal; Guilcher, Greg; Kohn, Donald B; Lewis, Victor; Marwaha, Ashish K; Murguia-Favela, Luis E; Narendran, Aru; Prokopishyn, Nicole L; Romero Garcia, Zulema; Suresh, Sneha

Keywords: Adenine Base Editing; Gene Editing; Gene Therapy Clinical Trial; Inborn Errors Of Immunity; Rare Diseases; Severe Combined Immune Deficiency

$606,576

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

Principal investigatorCIHR2022Operating Grant: Clinical Trials Projects

Keywords: Adenine Base Editing; Gene Editing; Gene Therapy Clinical Trial; Inborn Errors Of Immunity; Rare Diseases; Severe Combined Immune Deficiency

$2,426,302

Next Generation Anti-mitotics for Treatment-Refractory Cancer

Co-investigatorNSERC2010Collaborative Health Research Projects

Principal investigators: Schriemer, David

$233,500

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Adenine Base Editing Dear Professor Narendran, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency." (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Aru Narendran

Research

Latest papers

Latest funding

Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis.

Gene alterations in inborn errors of immunity and their presence in cancers: Implications for oncogenesis, progression, and outcomes.

Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.

PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma.

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma.

Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10.

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.

Using genetically engineered type 2 innate lymphoid cells to enhance T cell-based immunotherapies for the treatment of breast cancer

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

Next Generation Anti-mitotics for Treatment-Refractory Cancer

Frequent collaborators

Olga Kovalchuk

Luis Murguia-Favela

Vanessa Meier-Stephenson

Vanessa Meier-Stephenson

Adam Kirton

Victor Lewis

Cynthia Hawkins

Karl Riabowol

Dina El Demellawy

Eric Bouffet

Susanne Benseler

Daniel Morgenstern

Nicola Wright

Marc Kerba

Heinrike Schmeling

Nada Jabado

Laurie Ailles

Annie Huang

Sheila Singh

Vijay Ramaswamy

Aru Narendran

Research

Latest papers

Latest funding

Editorial Expression of Concern: Tumour exosome integrins determine organotropic metastasis.

Gene alterations in inborn errors of immunity and their presence in cancers: Implications for oncogenesis, progression, and outcomes.

Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study.

PV-10 enhances immune responses in hepatitis B vaccination through STING pathway.

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

Cancer-associated fibroblasts promote tumor progression in fusion-positive rhabdomyosarcoma.

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

Enitociclib, a selective CDK9 inhibitor: in&#xa0;vitro and in&#xa0;vivo preclinical studies in multiple myeloma.

Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10.

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and &#x3b3;-Radiation Therapy.

Using genetically engineered type 2 innate lymphoid cells to enhance T cell-based immunotherapies for the treatment of breast cancer

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

Next Generation Anti-mitotics for Treatment-Refractory Cancer

Frequent collaborators

Olga Kovalchuk

Luis Murguia-Favela

Vanessa Meier-Stephenson

Vanessa Meier-Stephenson

Adam Kirton

Victor Lewis

Cynthia Hawkins

Karl Riabowol

Dina El Demellawy

Eric Bouffet

Susanne Benseler

Daniel Morgenstern

Nicola Wright

Marc Kerba

Heinrike Schmeling

Nada Jabado

Laurie Ailles

Annie Huang

Sheila Singh

Vijay Ramaswamy

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma.

Targeting Oral Squamous Cell Carcinoma with Combined Polo-Like-Kinase-1 Inhibitors and γ-Radiation Therapy.